Abiraterone acetate + prednisolone treatment beyond prostate specific antigen and radiographic progression in metastatic castration-resistant prostate cancer patients
Urologic Oncology: Seminars and Original Investigations
Nov 18, 2017
Biro K, et al. - An inquiry was pursued with regard to the overall survival (OS) of chemotherapy refractory patients with metastatic castration-resistant prostate cancer who were treated with abiraterone acetate + prednisolone (AA + P) beyond prostate-specific antigen (PSA) and radiographic progression (PRP) until clinical progression in comparison to patients treated until PRP. The independent factors of longer OS were discovered to be low levels of AP at the start of treatment, systemic therapy applied after AA + P and treatment beyond PRP, in metastatic castration-resistant prostate cancer.
Go to Original
Sign-up to continue reading. It is free & takes less than 2 mins
45 lakhs+ doctors trust M3 globally
Free & unlimited access to original articles and quizzes
Secure: we never sell your data
This article is only available to members. Are you a doctor? Click here to signup for free.
Try M3 India / Log In